Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation (NASDAQ: LEGN) generates frequent news as a global cell therapy company focused on CAR‑T treatments for cancer. News coverage for Legend Biotech often centers on CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), its BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma, as well as updates on its broader pipeline of cell therapy programs.
Investors and observers following LEGN news can expect regular announcements on clinical data from the CARTITUDE program in multiple myeloma, including long‑term progression‑free survival results and analyses of earlier‑line use. Company press releases also highlight presentations at major medical meetings such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), where Legend Biotech shares outcomes from CARVYKTI and investigational candidates like LUCAR‑G39D, LB2102, and LB1908.
Legend Biotech’s news flow includes regulatory milestones, such as FDA and European Commission label updates for CARVYKTI to incorporate overall survival data and new safety information. The company also reports on manufacturing and infrastructure developments, including expansion of its Raritan, New Jersey cell therapy facility and commercial production in Ghent, Belgium, which are intended to support growing global demand.
Quarterly earnings releases and related Form 6‑K filings provide financial updates on collaboration revenue from CARVYKTI, license revenue from agreements with partners, operating expenses, cash and time deposits, and progress toward profitability. Corporate news items may also cover executive appointments, participation in investor conferences, and strategic priorities outlined at healthcare investment events.
For users tracking LEGN, this news page offers a centralized view of Legend Biotech’s clinical, regulatory, manufacturing, and financial announcements, helping contextualize the company’s evolution in the cell therapy and oncology landscape.
Legend Biotech (NASDAQ: LEGN) will present six posters on CARVYKTI® (ciltacabtagene autoleucel) at the Tandem Meetings, Feb 4-7, 2026, summarizing clinical and real-world evidence across CARTITUDE trials. Presentations highlight consistent, durable efficacy and safety signals and note clinically meaningful quality-adjusted survival gains, especially when CARVYKTI is used earlier in the multiple myeloma treatment continuum. CARVYKTI is the first and only BCMA-targeted CAR-T approved for patients with at least one prior therapy and is commercially available in 14 countries. The release also details important safety information, including CRS, neurologic toxicities, and warnings from CARTITUDE-1 and -4.
Legend Biotech (NASDAQ: LEGN) provided commercial and clinical updates and outlined 2026 priorities ahead of its Jan 14, 2026 J.P. Morgan presentation. Key highlights: CARVYKTI has treated >10,000 patients to date; global availability expanded to >279 sites across 14 markets; Raritan manufacturing expansion adds installed capacity to support treatment of up to 10,000 patients annually. Regulatory labels in the U.S. and EU now include an overall survival benefit from CARTITUDE-4. Median PFS of 50.4 months reported for certain patients. Company expects CARVYKTI franchise profitability in FY2025 and company-wide operating profit in 2026. Cash and time deposits were approximately $1.0 billion as of Sept 30, 2025. First-in-human in vivo dosing completed; in vivo readouts expected 2H 2026.
Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang, Ph.D. will present company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT.
The presentation will be available via a live webcast on Legend Biotech's Investor Relations website, and a replay will be posted approximately 48 hours after the live event.
Legend Biotech (NASDAQ: LEGN) reported long-term and first-in-human CAR-T data at ASH 2025 for CARVYKTI® (ciltacabtagene autoleucel) and allogeneic candidate LUCAR-G39D.
Key clinical highlights: median PFS of 50.4 months in triple-class-exposed patients after one CARVYKTI® infusion; CARTITUDE-4 standard-risk 30-month PFS 71.0% (CARVYKTI®) vs 43.2% (SOC); as-treated 30-month PFS 80.5%. All 26 patients with 12-month MRD-negative CR remained progression-free at 30 months. LUCAR-G39D (N=16) showed ORR 75% and CR 37.5% with manageable safety at median follow-up 6.1 months.
Safety: CARVYKTI® trials (N=285) reported CRS in 84% (Grade ≥3, 4%), ICANS in 13%, and parkinsonism in 3%. LUCAR-G39D reported CRS in 56.3% and serious AEs in 25% of patients. The company noted >9,000 patients treated globally.
Legend Biotech (NASDAQ: LEGN) announced the official opening of a 31,000-square-foot state-of-the-art R&D facility at 2300 Market Street, Philadelphia on November 13, 2025. The site is fully operational and will support CAR-T research and development across potential oncology and immunology indications.
The Philadelphia center expands Legend’s U.S. footprint (company employs over 1,400 U.S. staff), will hire approximately 55 full-time team members, and complements existing R&D in Piscataway plus manufacturing sites in Raritan and Morris Plains, New Jersey.
Legend Biotech (NASDAQ: LEGN) reported third quarter 2025 results on November 12, 2025, highlighting CARVYKTI net trade sales of ~$524 million and updated U.S. and EC labels to include an overall survival (OS) benefit from CARTITUDE-4. The company reported cash and time deposits of ~$1.0 billion as of September 30, 2025 and has treated over 9,000 patients to date. Legend initiated commercial production at its Tech Lane facility in Ghent and expects CARVYKTI profitability by year-end and company-wide profitability in 2026.
Legend Biotech (NASDAQ: LEGN) announced 10 presentations at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.
The program includes two oral and seven poster presentations on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma and an oral presentation of first-in-human Phase 1 data for Lucar-G39D, an allogeneic anti-CD20/CD19 dual-CAR gamma delta T cell therapy for relapsed/refractory B-cell NHL.
CARVYKTI is noted as commercially available in 14 countries and used to treat more than 9,000 patients to date.
Legend Biotech (NASDAQ: LEGN) will host a live investor conference call and webcast at 8:00 AM ET on Wednesday, November 12, 2025 to review third quarter 2025 results. Senior leaders will provide an overview of the company’s performance for the quarter.
Investors can join the live audio webcast via the company weblink. A replay of the webcast and the earnings news release will be posted in the Investor Relations site under Events and Presentations approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference. The company's CEO, Dr. Ying Huang, will engage in a fireside chat on September 9, 2025, at 4:05 p.m. ET in New York.
Investors can access the live webcast through Legend Biotech's Investor Relations website section, with a replay becoming available approximately 48 hours after the event.
Legend Biotech (NASDAQ: LEGN) has appointed Carlos Santos as its new Chief Financial Officer, effective immediately. Santos, who brings extensive experience from pharmaceutical and technology sectors, joins from AstraZeneca where he served as CFO for US Oncology. He succeeds Jessie Yeung, who has been interim CFO since January 2025.
In his new role, Santos will oversee Legend's financial operations with a focus on maintaining a strong balance sheet and achieving profitability. The company aims to reach companywide profitability in 2026, driven by the success of their CAR-T cell therapy franchise, CARVYKTI®.
FAQ
What is the current stock price of Legend Biotech (LEGN)?
What is the market cap of Legend Biotech (LEGN)?
